This grant, the Alzheimer’s Disease Therapeutics Program, is for supporting investigators in developing new drugs for Alzheimer’s disease prevention or treatment. It specifically targets researchers with promising small molecule compounds who need external drug development expertise and infrastructure. As an adjunct to the NIH Blueprint Neurotherapeutics Program, it provides access to a virtual pharma network of contract research organizations, technical and regulatory experts, and project managers with extensive biopharma-industry experience. The long-term objective is to advance projects from medicinal chemistry optimization through Phase I clinical trials and facilitate industry partnerships for further development.
Opportunity ID: 205193
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AG-13-014 |
| Funding Opportunity Title: | Alzheimer’s Disease Therapeutics Program (U01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.273 — Alcohol Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 31, 2012 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jan 14, 2013 |
| Current Closing Date for Applications: | Jan 14, 2013 |
| Archive Date: | Feb 14, 2013 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments Private institutions of higher education Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities For profit organizations other than small businesses City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The goal of this Funding Opportunity Announcement (FOA) is to provide support for investigators to develop new drugs for the prevention or treatment of Alzheimers disease (AD). Specifically, this initiative is aimed at researchers who have promising small molecule compounds but lack outside drug development expertise and infrastructure support to advance these compounds to the clinic. This Alzheimers Disease Therapeutics Program adjunct to the NIH Blueprint Neurotherapeutics Program will allow investigators access to a virtual pharma network of contract research organizations, technical and regulatory experts and project managers, with extensive biopharma-industry experience. The long-term goal of the Alzheimers Disease Therapeutics Program is to advance projects from medicinal chemistry optimization through Phase l clinical trials and facilitate industry partnership for their further development. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-13-014.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| ADOBE-FORMS-B2 | Adobe-Forms-B2 | PKG00150550 | Dec 14, 2012 | Jan 14, 2013 | View |
Package 1
Mandatory forms
205193 RR_SF424_1_2-1.2.pdf
205193 PerformanceSite_1_4-1.4.pdf
205193 RR_OtherProjectInfo_1_3-1.3.pdf
205193 RR_KeyPersonExpanded_1_2-1.2.pdf
205193 PHS398_CoverPageSupplement_1_4-1.4.pdf
205193 PHS398_ResearchPlan_1_3-1.3.pdf
205193 PHS398_Checklist_1_3-1.3.pdf
Optional forms
205193 RR_SubawardBudget30-1.2.pdf
205193 PHS398_ModularBudget_1_2-1.2.pdf
205193 RR_Budget-1.1.pdf
205193 PHS_CoverLetter_1_2-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
